Jun Liang

This inventor holds 48 USPTO granted patents and 27 published patent applications, plus 5 CIPO patents and 29 EPO patents, primarily in Cancer Therapeutics. Top assignees: Genentech, Inc., Array Biopharma Inc., Constellation Pharmaceuticals, Inc.. Active years: 2009-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jun Liang. Retrieved from https://idiyas.com/inventor/jun-liang

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 48 (Patent Applications = 27)

% Patents Active = 70.8

CIPO Patents = 5 (Patent Applications = 3)

EPO Patents = 29 (Patent Applications = 37)

Average Co-Inventor Count = 11.0

ph-index = 10

Forward Citations = 258(Granted Patents)

Location History:

Palo Alto, NJ (US) (2009)
Palo Alto, CA (US) (2009 - 2019)
South San Francisco, CA (US) (2012 - 2021)
Los Altos Hills, CA (US) (2017 - 2023)

Company Filing History:

Constellation Pharmaceuticals, Inc.

patents

4. 2 out of 181

F. Hoffmann-La Roche Ag

Merck Sharp + Dohme Corp.

F. Hoffman-Laroche, Ag (Ex-US)

Hoffman-Laroche, Inc. (US Only)

patent

where one patent can have more than one assignee

Years Active: 2009-2025

Loading Chart...

Areas of Expertise:

Isoquinoline Compounds

Naphthyridine Compounds

IRAK4 Modulators

Estrogen Receptor Modulators

AKT Protein Kinase Inhibitors

Pyrimidyl Cyclopentanes

Pyrazolo Compounds

Therapeutic Compounds

Heterocyclic Compounds

Tetrahydroisoquinoline

Tetrahydro-pyrido[3,4-b]indole

Histone Demethylase Inhibitors

48 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12473301 - Isoquinoline compounds for the treatment of cancer (2025-11-18),

2. 12378249 - Isoquinoline compounds and uses thereof (2025-08-05),

3. 12297210 - Naphthyridine compounds and uses thereof (2025-05-13),

4. 12233052 - Tetrahydro-pyrido[3,4-b]indole estrogen receptor modulators and uses thereof (2025-02-25),

5. 12187709 - Lactams as CBL-B inhibitors selective over C-CBL (2025-01-07),

6. 11612606 - 8-aminoisoquinoline compounds and uses thereof (2023-03-28),

7. 11566003 - Isoquinolines as inhibitors of HPK1 (2023-01-31),

8. 11034698 - Pyrazolo[ 1,5a]pyrimidine derivatives as IRAK4 modulators (2021-06-15),

9. 11034692 - Naphthyridines as inhibitors of HPK1 (2021-06-15),

10. 10988478 - Pyrazolo[1,5a]pyrimidine derivatives as IRAK4 modulators (2021-04-27),

11. 10966963 - Tetrahydro-pyrido[3,4-b]indole estrogen receptor modulators and uses thereof (2021-04-06),

12. 10899772 - IRAK4 modulators (2021-01-26),

13. 10654867 - Heteroaryl estrogen receptor modulators and uses thereof (2020-05-19),

14. 10407424 - Naphthyridines as inhibitors of HPK1 (2019-09-10),

15. 10399939 - Tetrahydronaphthalene estrogen receptor modulators and uses thereof (2019-09-03),

Title: The Innovative Journey of Jun Liang

Introduction: Jun Liang, a visionary inventor based in Palo Alto, CA, has made significant contributions to the field of technology through his groundbreaking inventions and patents.

Latest Patents: Jun Liang holds several patents in the areas of artificial intelligence, machine learning, and robotics, showcasing his expertise in cutting-edge technologies that are shaping the future.

Career Highlights: With a background in computer science and engineering, Jun Liang has a successful track record of developing innovative solutions that have revolutionized industries. His work has been recognized for its creativity and impact on society.

Collaborations: Jun Liang has collaborated with leading tech companies, research institutions, and universities to further advance his inventions and bring them to market. His partnerships have been instrumental in driving forward technological advancements.

Conclusion: Jun Liang's passion for innovation and dedication to pushing the boundaries of technology have solidified his reputation as a pioneering inventor in the vibrant tech hub of Palo Alto, CA. His continued pursuit of excellence promises a future filled with groundbreaking inventions that will shape the world we live in.

Profile summary based on public USPTO records.